NCT04022239View on ClinicalTrials.gov

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Hematopoietic and Lymphoid System Neoplasm
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo stem cell transplantation

DRUG

Bendamustine

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Filgrastim-sndz

Given SC

DRUG

Fludarabine

Given IV

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Tacrolimus

Given IV and PO

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER